Nowell J Ganey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nowell J Ganey has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amelia March
The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA
1 shared publication - Corbin Bachmeier
The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA
1 shared publication - Daniel Paris
Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA
1 shared publication - David Beaulieu-Abdelahad
The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA
1 shared publication - Ghania Ait-Ghezala
The Roskamp Institute, Sarasota, Florida, United States of America
1 shared publication - Michael Mullan
Roskamp Institute, Sarasota, Florida, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 17
Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease
Aβ deposits represent a neuropathological hallmark of Alzheimer's disease (AD). Both soluble and insoluble Aβ species are considered to be responsible for initiating the pathological cascade that eventually leads to AD. Therefore, the identification of therapeutic approaches that can lower Aβ production or accumulation remains a priority. NFκB has been shown to regulate BACE-1 expression level, the rate limiting enzyme responsible for the production of Aβ. We therefore explored whether the known NFκB inhibitor celastrol could represent a suitable compound for decreasing Aβ production and accumulation in vivo.
- 1 January 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 17
Open AccessReduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease
Aβ deposits represent a neuropathological hallmark of Alzheimer's disease (AD). Both soluble and insoluble Aβ species are considered to be responsible for initiating the pathological cascade that eventually leads to AD. Therefore, the identification of therapeutic approaches that can lower Aβ production or accumulation remains a priority. NFκB has been shown to regulate BACE-1 expression level, the rate limiting enzyme responsible for the production of Aβ. We therefore explored whether the known NFκB inhibitor celastrol could represent a suitable compound for decreasing Aβ production and accumulation in vivo.